Prospective Study of Bioactive Stent Implantation During Primary Percutaneous Coronary Intervention

  • Yoga Yuniadi Department of Cardiology and Vascular Medicine, Faculty of Medicine, University of Indonesia National Cardiovascular Center Harapan Kita, Jakarta

Abstract

Background. Limited data are available on efficacy and safety of bioactive stent implantation in acute STEMI patient. This study aims to evaluate efficacy titanium nitrit-oxide stent implantation during primary percutaneous coronary intervention.
Methods and Results. Thirty eight patients (age of 55.9 ± 8.35 years) presenting with less than 12 hours onsetacute STEMI enrolled in this study. After titanium nitrit oxide bioactive stent implantation then 12 months clinical follow up was performed. Infarct location were anterior (58%) and Killip class I (82%) in majority of cases. Average door to balloon time is 85.7 ± 33.88 minutes. Cilprit lesions have characteristics of simple lesion as it comprised of almost 90% of denovo and 60.5% were type A lesion. Proportion of history of myocardial infarction is higher in patients experienced of MACE but other characteristics were similar as compare to non-MACE group. MACE-free survival is 83.6% during 12 months follow up.
Conclusion. In our population, implantation of bioactive stent during primary PCI of STEMI patient is safe and effective. Twelve months MACE-free survival is similar to other study using similar stent or drug eluting stent.

Downloads

Download data is not yet available.

References

Silber S, Albertsson P, Aviles FF, Camici PG, Colombo A, Hamm C, Jorgensen E, Marco J, Nordrehaug JE, Ruzyllo W, Urban P, Stone GW, Wijns W. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J. 2005;26(8):804-847.

Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet. 2003;361(9351):13-20.

Zhu MM, Feit A, Chadow H, Alam M, Kwan T, Clark LT. Primary stent implantation compared with primary balloon angioplasty for acute myocardial infarction: a meta-analysis of randomized clinical trials. Am J Cardiol. 2001;88(3):297-301.

Karjalainen PP, Ylitalo A, Niemela M, Kervinen K, Makikallio T, Pietili M, Sia J, Tuomainen P, Nyman K, Airaksinen KE. Titanium-nitride-oxide coated stents versus paclitaxel-eluting stents in acute myocardial infarction: a 12-months follow-up report from the TITAX AMI trial. EuroIntervention. 2008;4(2):234-241.

Andersen HR, Nielsen TT, Rasmussen K, Thuessen L, Kelbaek H, Thayssen P, Abildgaard U, Pedersen F, MAdsen JK, Grande P, Viladsen AB, Krusell LR, Haghfelt T, Lomholt P, Husted SE, Vigholt E, Kijargard HK, Mortensen LS. A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. N Engl J Med. 2003;349:733-742.

Grines CL, Westerhausen DRJ, Grines LL, Hanlon JT, Logemann TL, Niemela M, Weaver WD, Graham M, Boura JA, O’Neill WW, Belestrini C. A randomized trial of transfer for primary angioplasty versus on-site thrombolysis in patients with high-risk myocardial infarction: the Air Primary Angioplasty in Myocardial Infarction study. J Am Coll Cardiol. 2002;39:1713-1719.

Dalby M, Bouzamondo A, Lechat P, Montalescot G. Transfer for primary angioplasty versus immediate thrombolysis in acute myocardial infarction: a meta-analysis. Circulation. 2003;108:1809-1814.

Henry TD, Unger BT, Sharkey SW. Design of a standardized system for transfer of patients with ST-elevation myocardial infarction for percutaneous coronary intervention. Am Heart J. 2005;150:373-384.

Kushner FG, Hand M, Smith SC, Jr., King SB, 3rd, Anderson JL, Antman EM, Bailey SR, Bates ER, Blankenship JC, Casey DE, Jr., Green LA, Hochman JS, Jacobs AK, Krumholz HM, Morrison DA, Ornato JP, Pearle DL, Peterson ED, Sloan MA, Whitlow PL, Williams DO. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2009;54(23):2205-2241.

Nordmann AJ, Hengstler P, Harr T, Young J, Bucher HC. Clinical outcomes of primary stenting versus balloon angioplasty in patients with myocardial infarction: a meta-analysis of randomized controlled trials. Am J Med. 2004;116(4):253-262.

Pasceri V, Patti G, Speciale G, Pristipino C, Richichi G, Di Sciascio G. Meta-analysis of clinical trials on use of drug-eluting stents for treatment of acute myocardial infarction. Am Heart J. 2007;153(5):749-754.

Kastrati A, Dibra A, Spaulding C, Laarman GJ, Menichelli M, Valgimigli M, Di Lorenzo E, Kaiser C, Tierala I, Mehilli J, Seyfarth M, Varenne O, Dirksen MT, Percoco G, Varricchio A, Pittl U, Syvanne M, Suttorp MJ, Violini R, Schomig A. Meta-analysis of randomized trials on drug-eluting stents vs. bare-metal stents in patients with acute myocardial infarction. Eur Heart J. 2007;28(22):2706-2713.

De Luca G, Stone GW, Suryapranata H, Laarman GJ, Menichelli M, Kaiser C, Valgimigli M, Di Lorenzo E, Dirksen MT, Spaulding C, Pittl U, Violini R, Percoco G, Marino P. Efficacy and safety of drug-eluting stents in ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. Int J Cardiol. 2009;133(2):213-222.

Van de Werf F. Drug-eluting stents in acute myocardial infarction. N Engl J Med. 2006;355(11):1169-1170.

Montalescot G, Barragan P, Wittenberg O, Ecollan P, Elhadad S, Villain P, Boulenc JM, Morice M, Maillard L, Pansieri M, Choussat R, Pinton P, for the ADMIRAL Investigators. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med. 2001;344:1895-1903.

Lee DP, Herity NA, Hiatt BL, Fearon WF, Rezaee M, Carter AJ, Huston M, Schreiber D, DiBattiste PM, Yeung AC. Adjunctive platelet glycoprotein IIb/IIIa receptor inhibition with tirofiban before primary angioplasty improves angiographic outcomes: results of the TIrofiban Given in the Emergency Room before Primary Angioplasty (TIGER-PA) pilot tria. Circulation. 2003;107:1497-1501.

Gyongyosi M, Domanovits H, Benzer W, Haugk M, Heinisch B, Sodeck G, Hodl R, Gaul G, Bonner G, Wojta J, LAggner A, Glogar D, Huber K. Use of abciximab prior to primary angioplasty in STEMI results in early recanalization of the infarct-related artery and improved myocardial tissue reperfusion—results of the Austrian multi-centre randomized ReoPro-BRIDGING Study. Eur Heart J. 2004;25:2125-2133.

Van’t Hof AW, Ernst N, De Boer MU, De Winter R, Boersma E, Bunt T, Petronio S, Marcel Gosselink AT, Jap W, Holak F, Hoorntje JC, Suyapranata H, Dambrink JH, Zijlstra F. Facilitation of primary coronary angioplasty by early start of a glycoprotein 2b/3a inhibitor: results of the ongoing tirofiban in myocardial infarction evaluation (On-TIME) trial. Eur Heart J. 2004;25:837-846.

Antman EM, Anbe DT, Amstrong PW, Bates ER, Green LA, Hand M, Hochman JS, Krumholz HM, Kushner FG, Lamas GA, Mullany CJ, Ornato JP, Pearle DL, Sloan MA, Smith SC, Jr., Alpert JS, Anderson JL, Faxon DP, Fuster V, Gibbons RJ, Gregoratos G, Halperin JL, Hiratzka LF, Hunt SA, Jacobs AK. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction-Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation. 2004;110:588-636.
Views & Downloads
Abstract views: 256   
PDF (Bahasa Indonesia) downloads: 134   
How to Cite
Yuniadi, Y. (1). Prospective Study of Bioactive Stent Implantation During Primary Percutaneous Coronary Intervention. Indonesian Journal of Cardiology, 32(3), 162-9. https://doi.org/10.30701/ijc.v32i3.93
Section
Clinical Research